AI MARKET SCANNING

Mereo Biopha-Adr

📅 Next Catalyst: Nov 09, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +4.70%
MAX GAP RECORD +35.66%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $MREO
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 09, 2026 Earnings Release 2026-11-09 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 11, 2026 Earnings Release 2026-08-11 (BEFORE OPEN)
+35.66%
May 12, 2026 Earnings Release 2026-05-12 (BEFORE OPEN)
+0.82%
Mar 19, 2026 Earnings Release 2026-03-19 (BEFORE OPEN)
-0.57%
Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE)
+1.13%
Aug 12, 2025 Earnings Release 2025-08-12 (BEFORE OPEN)
-1.64%
May 13, 2025 Earnings Release 2025-05-13 (BEFORE OPEN)
+0.00%
Mar 26, 2025 Earnings Release 2025-03-26 (BEFORE OPEN)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 6.1%
Bullish Gaps (2)
Bearish Gaps (2)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $MREO

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗